Cargando…
Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
BACKGROUND: Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer’s disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences between amyloid-positive and amyloid-negative patients. However, the relationship...
Autores principales: | Mundada, Nidhi S., Rojas, Julio C., Vandevrede, Lawren, Thijssen, Elisabeth H., Iaccarino, Leonardo, Okoye, Obiora C., Shankar, Ranjani, Soleimani-Meigooni, David N., Lago, Argentina L., Miller, Bruce L., Teunissen, Charlotte E., Heuer, Hillary, Rosen, Howie J., Dage, Jeffrey L., Jagust, William J., Rabinovici, Gil D., Boxer, Adam L., La Joie, Renaud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517500/ https://www.ncbi.nlm.nih.gov/pubmed/37740209 http://dx.doi.org/10.1186/s13195-023-01302-w |
Ejemplares similares
-
Evaluation of a visual interpretation method for tau‐PET with (18)F‐flortaucipir
por: Sonni, Ida, et al.
Publicado: (2020) -
Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome
por: VandeVrede, Lawren, et al.
Publicado: (2023) -
Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020) -
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2023) -
(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)